Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2015 07:00 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell

FORT WASHINGTON, Pa., Sept. 22, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeff Hatfield, President and Chief...
September 08, 2015 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 Study of First-in-Class RORyt Inhibitor VTP-43742 in Autoimmune Disorders

Single ascending doses of VTP-43742 safe and generally well-tolerated, demonstrated once-daily pharmacokinetics Robust ex vivo biomarker response, suppressing pro-inflammatory IL-17A by more...
August 10, 2015 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Initiation of a Phase 1 Multiple Ascending Dose Study of VTP-43742 in Autoimmune Disorders

FORT WASHINGTON, Pa., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that it has initiated a Phase 1 multiple...
August 05, 2015 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

FORT WASHINGTON, Pa., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
August 04, 2015 16:10 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports Second Quarter 2015 Operating and Financial Results

Multiple potential milestones in 2H 2015 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a...
July 29, 2015 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Appoints Dr. John M. Leonard to Board of Directors

FORT WASHINGTON, Pa., July 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of John M. Leonard, M.D., to...
July 28, 2015 07:00 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Announce Second Quarter 2015 Financial Results on August 4, 2015

FORT WASHINGTON, Pa., July 28, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, August 4, 2015 at...
July 27, 2015 06:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and License Agreement for BACE Inhibitors

Vitae Expects to Receive Rights to BI-1147560 / VTP-36951 Company to Assess Program to Determine Next Steps FORT WASHINGTON, Pa., July 27, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc....
June 29, 2015 06:32 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Top-Line Results From Metformin Arm of Ongoing Phase 2 Clinical Trial of BI187004/VTP-34072 in Overweight Type 2 Diabetics

FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced top-line clinical efficacy results from the...
June 29, 2015 06:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Initiation of a Phase 1 Single Ascending Dose Study of VTP-43742 in Autoimmune Disorders

FORT WASHINGTON, Pa., June 29, 2015 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the initiation of a Phase 1 single ascending...